Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

Why does it matter? Because depression isn't a chemical you're missing — it's a circuit pattern you can reboot in five days

Dr. Nolan Williams has achieved the highest remission rates ever reported for treatment-resistant depression: 60 to 90% full remission, in five days, with no drugs. The mechanism behind those results also explains why psilocybin, MDMA, and ibogaine all work — and it demolishes the serotonin-deficit model psychiatry has built the last four decades around.

• A 5-day TMS protocol compresses 7.5 months of treatment using spaced learning theory, achieving 60–90% full remission in the most severe cases. • Depression is a timing disorder between two brain regions, not a serotonin deficiency — and TMS proves it by working in 1–5 days without touching serotonin at all. • Psilocybin and SNT-TMS produce antidepressant effects by breaking the exact same overconnected brain loop — the subgenual anterior cingulate fused to the default mode network. • Two-thirds of PTSD patients show clinically significant improvement from 1–3 MDMA sessions at 150–175 mg, with effects lasting years versus ketamine's 10-day average.

The once-daily TMS standard was underdosing by an order of magnitude — cramming 7.5 months into 5 days achieves 60–90% full remission

Once-daily TMS for six weeks is the neurological equivalent of studying for a final exam by reviewing your notes once a day for months. Spaced learning theory says the optimal consolidation window is every hour to an hour and a half. The standard protocol ignored that entirely.

The underdosing insight came from data: when researchers extended treatment past six weeks, more patients kept improving at month three, four, five. The dose ceiling was arbitrary. So Williams rebuilt the schedule from scratch. "We're going to give 7 and 1/2 months worth in 5 days using space learning theory." That means stimulation every hour, for 10 hours, for 5 consecutive days — 50 sessions, 90 minutes of total stimulation, timed to the brain's own memory-consolidation rhythm.

The results: somewhere between 60 and 90% of patients achieve full remission — "totally normal from a mood standpoint" — by the end of the week. Some have held that remission for four years. The signal is simple but precise: magnetic pulses fire the left dorsolateral prefrontal at the frequency the hippocampus uses to encode long-term memory. "Turn on, stay on, remember to stay on" — bypassing the hippocampus and delivering that consolidation signal directly to the prefrontal.

A handful of patients who remitted by Wednesday reported something Williams didn't anticipate. Independently, without any prompting, five or six of them described sitting at the beach at the end of the week experiencing spontaneous present-moment awareness — mindfulness without any meditation practice. He doesn't have controlled data on it yet, but the consistency across patients without any shared priming is difficult to dismiss.

Depression is a circuit arrhythmia, not a serotonin deficiency — and TMS dismantles the chemical-imbalance story by working without a molecule of serotonin

There's no serotonin involved. That's the finding, and it's the refutation. TMS achieves remission in one to five days without adding, blocking, or altering serotonin in any way. Williams is direct: "We're not giving anybody any serotonin. We're simply turning these brain regions on."

The circuit at stake is specific. The left dorsolateral prefrontal cortex — the brain's executive governor — is supposed to modulate the cingulate, the conflict-detection system responsible for the ruminative negative content that defines depression. When it's working, the prefrontal is the coach directing the players. In depression, the relationship inverts: the cingulate governs the prefrontal, driving the coach off the field. TMS exogenously restores that timing. The degree to which it succeeds — measurable on neuroimaging — correlates directly with antidepressant effect.

What makes the circuit model therapeutically important isn't just the mechanism — it's the message it sends patients. The chemical-imbalance frame communicates "there is something chemically missing with me." The circuit frame communicates something categorically different: "It's basically recalibrating a circuit that is re-calibratable." Williams reaches for the analogy deliberately. "It's just like an arrhythmia in the heart. It's like a broken leg. We can go in and do something and we can get somebody better."

Patients who relapse and return for more stimulation consistently report they no longer fear being permanently broken. That shift in illness identity — independent of the symptom relief itself — is a meaningful clinical outcome in its own right.

Psilocybin and TMS produce the exact same connectivity change in the brain — both unhook negative mood from self-representation through the same circuit

A magnetic field and a hallucinogenic compound with zero pharmacological overlap fix depression by doing the same thing to the same network.

David Nutt and Robin Carhart-Harris's neuroimaging work was the first to map what psilocybin does to the brain in real time. They expected increased activity. What they found was the opposite: global brain activity decreases, but connectivity patterns shift profoundly. The antidepressant-relevant change — the one that tracks with clinical improvement — is a downregulation of connectivity between the subgenual anterior cingulate and the default mode network. That is precisely the connectivity change Williams's SNT-TMS produces.

The mechanism makes intuitive sense once you understand the starting condition. In depression, the subgenual anterior cingulate and the default mode network are overconnected. The conflict-detection system is fused to the self-representation network. Patients don't just experience bad feelings; they experience themselves as the bad feeling. Williams describes it exactly: "You've got an overconnected negatively balanced system, conflict system that's kind of attached on to the self-representation and people feel stuck." When the effective treatment — whatever form it takes — loosens that coupling, "it unpairs those two systems."

Ketamine lands on the same circuitry. So does effective psychotherapy, at slower timescales. The convergence across interventions with completely different mechanisms of action is the signal: the therapeutic target in depression is not a neurotransmitter or a receptor subtype. It's a connectivity pattern between two networks that can be directly measured before and after any intervention that works.

Two-thirds of PTSD patients showed clinically significant improvement from 1–3 MDMA sessions — effects lasting years, not the 10 days a ketamine infusion averages

The MAPS trial numbers are unambiguous. About two-thirds of PTSD patients showed clinically significant improvement from one to a few sessions at the standard clinical dose of 150 to 175 milligrams. In earlier trials with longer follow-up, effects lasted "in the years range for some people."

Ketamine, by comparison, averages roughly a week and a half of relief per infusion. Patients typically need clustered dosing — multiple infusions over two weeks — and even then, durability is variable. Williams finds the MDMA-for-PTSD data more compelling precisely because of the durability differential.

The working model: MDMA opens a window of heightened neural plasticity during which traumatic memories reconsolidate differently. PTSD symptoms are, Williams notes, highly adaptive on a battlefield — the hypervigilance, the startle response, the hair-trigger threat detection. Evolution built the brain to hold fear learning tightly. Back home, those same responses are debilitating and useless. MDMA appears to create conditions under which the memory can be re-encoded and the conditioned response loses its grip.

For treatment-resistant PTSD — combat veterans in particular — this is a different therapeutic class entirely, not a better option within the existing pharmacological lineup. SSRIs can blunt symptoms. A two-thirds clinically significant response lasting years from one to three sessions is doing something categorically different.

The American Heart Association added depression as a cardiovascular risk factor — and TMS over the prefrontal cortex measurably decelerates the heart through a direct anatomical pathway

TMS applied to the left dorsolateral prefrontal cortex slows the heart. That's a replicable, anatomically specific finding — not a metaphor for mind-body connection.

Williams has mapped the pathway: magnetic pulse depolarizes the dorsolateral prefrontal → signal cascades through the anterior cingulate → insula → amygdala → nucleus tractus solitarius → vagus nerve → heart. Apply the same stimulation over visual cortex or motor cortex: no cardiac effect. It's specific to the prefrontal control region, and it's been replicated four or five times across independent labs, including Martin Arns's group in the Netherlands.

The American Heart Association has formalized the clinical implication: depression now sits as the fourth major risk factor for coronary artery disease, alongside hypertension, hyperlipidemia, and diabetes. Not correlated — independently causal enough to join the canonical list that has been stable for decades.

Williams uses heart-rate deceleration as a live probe of that brain-heart circuit's integrity. The finding reframes what untreated depression does to the body: the depressed brain is not just generating negative cognitions. It is continuously dysregulating the heart through a hardwired anatomical line. Treating depression aggressively is, simultaneously, treating the cardiovascular system.

Ibogaine gives combat veterans '10 years of psychotherapy in a night' — a 24-to-36-hour life review that resolves moral injury when nothing else has

No pharmacotherapy has a reliable answer for moral injury — the guilt soldiers carry from actions in combat that resulted in civilian harm. Ibogaine appears to reach it.

During an ibogaine session lasting 24 to 36 hours, users re-examine earlier life memories with eyes closed, but from a position of detached, third-party empathy — present in the scene but able to extend compassion to themselves and others involved in ways that waking consciousness does not permit. Williams's veterans — former Navy SEALs, Army Rangers — emerged from sessions saying they had forgiven themselves. "Which is huge," Williams says. That's not a soft outcome. It's the resolution of a burden that years of therapy and medication have consistently failed to touch.

Ibogaine carries the highest risk profile of any compound Williams studies. It affects cardiac conduction, and that risk is real. But it's manageable: pre-screening electrocardiograms can identify patients at elevated cardiac risk and exclude them before administration — which is precisely what his team did for the first formal neurobiological study of ibogaine in special operations veterans.

Nobody takes ibogaine recreationally. The duration alone — sometimes approaching 36 hours — eliminates that possibility. The experience is hard and demanding. Williams suspects that difficulty may be inseparable from its therapeutic potency for the cases where everything else has failed.

A controlled ayahuasca trial in Brazilian prisons found statistically significantly lower recidivism — suggesting psychedelics reshape behavioral circuitry, not just mood

Prisoners who received ayahuasca sessions returned to prison at statistically significantly lower rates than controls who didn't. That finding stretches the psychedelic question past depression and PTSD into behavior and decision-making.

The chemistry is worth noting. Of the 10,000 to 20,000 plant species in the Amazon, traditional practitioners identified the exact two-plant combination — a DMT-containing plant cooked together with a reversible monoamine oxidase inhibitor plant — then discovered that cooking them together for five to ten hours produces a preparation in which the MAOI prevents GI breakdown of the DMT, allowing it to cross the blood-brain barrier. A standard irreversible MAOI prescription would trigger serotonin syndrome. The plant-derived reversible version hits the precise pharmacological window. The level of embedded precision in that traditional preparation is striking.

Williams is careful with the prison finding — he doesn't know the specific crimes, and he is not advocating psychedelics in criminal justice settings. But the implication is hard to contain: if a single ayahuasca experience measurably reduces return-to-crime, something is shifting in the circuitry governing impulsive and antisocial behavior, not merely mood. The therapeutic scope of these compounds may be substantially wider than psychiatry's current framing of them as antidepressants.

Psychiatry 3.0 has one measurable circuit target — and every treatment that works is already converging on it

What Williams is really describing is the end of trial-and-error mood medicine. If the subgenual anterior cingulate's overconnection to the default mode network is the actual lesion in depression — measurable before and after any intervention — then the field has a tractable engineering problem for the first time: which approach most efficiently decouples those two systems, with what durability, for which patient?

TMS, psilocybin, ketamine, MDMA, ibogaine — all landing at the same address through completely different mechanisms. Wherever they overlap, that overlap is signal.

The chemical-imbalance era is over. What replaces it is a circuit you can fix.

---

Topics: depression, TMS, neuromodulation, psilocybin, MDMA, ketamine, ibogaine, ayahuasca, PTSD, psychiatry, neuroscience, brain stimulation, neuroplasticity, serotonin hypothesis, cardiac risk, SNT protocol, psychedelics, circuit-based psychiatry